RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Saving lives one breath at a time

Mar 9, 2010 - 5:00:00 AM
Following the secondment, Trevor Smith of Bedfont commented: It was very important for us to be able to show that our instruments are fit for purpose, and scientifically sound. NPL helped us demonstrate this by revealing the close agreement between analytical techniques of gas analysis, traceable calibration standards and our breath monitoring equipment.

 
[RxPG] The National Physical Laboratory (NPL) has completed a project to help a UK company diagnose medical conditions through monitoring patients' breath.

Bedfont Scientific Ltd is one of the market leaders in developing personal diagnostic gas sensors for the medical market. Its sensors can continuously monitor levels of certain gases in human breath, and could potentially be used in place of certain invasive blood tests.

In order to extend their position in this market, and confirm their reputation for quality and accuracy, Bedfont required its instruments to be independently evaluated.

To achieve this, Managing Director Trevor Smith, was seconded to NPL under a scheme called Measurement for Innovators. This gave Bedfont direct access to NPL's scientific expertise and state-of-the-art facilities.

NPL helped Bedfont determine key performance parameters for two types of electrochemical breath sensors, one for measuring carbon monoxide and the other for measuring hydrogen. Bedfont tested their instruments against the concentrations of these gases that are relevant to the medical market.

The presence of certain levels of these gases in human breath is medically extremely important. One sensor, for example, shows whether a patient has been smoking, allowing healthcare workers to demonstrate potentially harmful carbon monoxide levels to smokers. Another detects if a patient is suffering from gut disorder, indicated by increased levels of hydrogen in a patient's breath.

NPL confirmed that the sensors measured these gases within their technical specification, had linear response characteristics, and had negligible interferences from certain breath gases, which may cause false positives.

The results of the tests carried out at NPL provided Bedfont with the necessary independent verification of its sensors giving it a potential edge over international competitors, and the opportunity to expand within the UK's National Health Service and into other global markets.

Nick Martin, Senior Research Scientist at NPL, said: Measurement is critical to many areas of the medical industry and can assist in an improved understanding of some diseases. Personalised breath sensors can provide additional diagnostic information for making medical decisions. As the trend for their use widens it will be necessary to establish performance standards and to independently verify equipment using traceable gas mixtures. Companies that meet the standards will find it easier to penetrate the target markets of the future.

Following the secondment, Trevor Smith of Bedfont commented: It was very important for us to be able to show that our instruments are fit for purpose, and scientifically sound. NPL helped us demonstrate this by revealing the close agreement between analytical techniques of gas analysis, traceable calibration standards and our breath monitoring equipment.

Working with NPL has been an excellent experience and one we would like to develop in the future with more of our products




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)